170259 ⎘
Assays involving biological materials from specific organisms or of a specific nature from viruses; RNA viruses; Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus; Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV HIV-1, HIV-2
Sub-classes:Sexually Transmitted Infection Testing from Human Dried Blood Spots Collected Remotely
#2SINGLE-MOLECULE PLATFORM FOR DRUG DISCOVERY: METHODS AND APPARATUSES FOR DRUG DISCOVERY, INCLUDING DISCOVERY OF ANTICANCER AND ANTIVIRAL AGENTS
#3IMMUNOASSAY FOR DETECTING BIOLOGICALLY ACTIVE PROTEINS
#4DNA DISPLAY OF FOLDED RNA LIBRARIES ENABLING RNA-SELEX WITHOUT REVERSE TRANSCRIPTION
#5METHODS AND USES OF CRISPR CASCADE REACTIONS FOR CRISPR DIAGNOSTICS
#6DEVICES, SOLUTIONS AND METHODS FOR SAMPLE COLLECTION RELATED APPLICATIONS, ANALYSIS AND DIAGNOSIS
#7TRANSGLUTAMINASE SUBSTRATES FOR LABELING
#8DIAGNOSTIC, PROGNOSTIC, THERAPEUTIC AND SCREENING PROTOCOLS
#9RECOMBINANT GP120 PROTEIN WITH V1-LOOP DELETION
#10SIMULTANEOUS DETECTION OF ANTIGENS AND ANTIGEN SPECIFIC ANTIBODIES IN A GUINEA PIG MODEL SYSTEM
#11OPTIMIZED CROSSLINKERS FOR TRAPPING A TARGET ON A SUBSTRATE
#12Methods and compositions for assessing antibody specificities
#13Anti-HVEM Antibodies
#14SINGLE-MOLECULE PLATFORM FOR DRUG DISCOVERY: METHODS AND APPARATUSES FOR DRUG DISCOVERY, INCLUDING DISCOVERY OF ANTICANCER AND ANTIVIRAL AGENTS
#15Enhanced expression of polo-like kinase 3 (PLK3) in human immunodeficiency virus (HIV)-infected cells
#16CALIBRATION OF ELISA FOR CLINICAL ANTIBODY RESPONSE BY QUANTITATIVE MASS SPECTROMETRY
#17CALIBRATION OF ELISA FOR CLINICAL ANTIBODY RESPONSE BY QUANTITATIVE MASS SPECTROMETRY
#18TRANSGLUTAMINASE SUBSTRATES FOR LABELING
#19Methods and compositions for assessing antibody specificities
#20Optimized crosslinkers for trapping a target on a substrate
#21HIV SEROSIGNATURES FOR CROSS-SECTIONAL INCIDENCE ESTIMATION
#22Recombinant gp120 protein with V1-loop deletion
#23Method for the evaluation of antiretroviral therapy (ART) effectiveness in HIV-1 CD4+CD89+ cellular reservoirs
#24HIV antibody derivatives with dual antiviral and immunomodulatory activities from CD4 and GP41
#25Synthetic peptide for detecting HIV-1
#26METHODS AND APPARATUS FOR CONDUCTING MULTIPLE MEASUREMENTS ON A SAMPLE
#27Methods and compositions for assessing antibody specificities
#28Cofilin phosphorylation for quantifying CD4 T cell damage and predict CD4 T cell recovery from anti-retroviral therapy
#29OPTIMIZED CROSSLINKERS FOR TRAPPING A TARGET ON A SUBSTRATE
#30MULTIVALENT MONO- OR BISPECIFIC RECOMBINANT ANTIBODIES FOR ANALYTIC PURPOSE
#31METHODS AND COMPOSITIONS FOR ASSESSING ANTIBODY SPECIFICITIES
#32Rapid nucleic acid detection without sample preparation
#33Method and device of using aqueous two-phase systems (ATPS) for enhancing diagnostics for sexually transmitted infections
#34Compositions and methods for determining resistance to inhibitors of virus entry using recombinant virus assays
#35Single-molecule platform for drug discovery: methods and apparatuses for drug discovery, including discovery of anticancer and antiviral agents
#36Compounds that bind to human immunodeficiency virus rev response element
#37Diagnostic, prognostic, therapeutic and screening protocols
#38METHODS AND APPARATUS FOR CONDUCTING MULTIPLE MEASUREMENTS ON A SAMPLE
#39Method for detecting HIV-1-specific antibodies using clade C env polypeptides
#40HIV CLINICAL PLAN
#41COMPOSITIONS, SYSTEMS AND METHODS FOR GENE EXPRESSION NOISE DRUG SCREENING AND USES THEREOF
#42Method and system for detection of disease agents in blood
#43SCREENING METHODS FOR IDENTIFYING AND TREATING HIV-1 INFECTED PATIENT SUB-POPULATIONS SUITABLE FOR LONG TERM ANTI-CCR5 AGENT THERAPY
#44Compositions and Methods for Evaluating Viral Receptor/Co-Receptor Usage and Inhibitors of Virus Entry Using Recombinant Virus Assays
#45Broadly neutralizing antibodies against HIV-1 and use thereof
#46Methods for determining the risk of cardiovascular disease in a subject having a chronic viral infection through the measurement of lysophosphatidic acid
#47Systems and methods for determining cyclic nucleotide concentration and related pathway activation
#48Compositions and methods to prevent cancer by stabilizing p53 through non MDM2-mediated pathways
#49Optimized crosslinkers for trapping a target on a substrate
#50Single-Molecule Platform For Drug Discovery: Methods And Apparatuses For Drug Discovery, Including Discovery Of Anticancer And Antiviral Agents
#51Compositions for preventing and/or treating an infection by an HIV-1 virus
#52Multi-color reporter cells for detecting HIV-1
#53Methods for screening compounds for treating or preventing a viral infection or a virus-related condition
#54Devices, solutions and methods for sample collection related applications, analysis and diagnosis
#55Fluorogenic probes and their use in quantitative detection of target RNA sequences
#56Cell identification method
#57Aggregation-assisted separation of plasma from whole blood
#58Method and system for detection of disease agents in blood
#59Methods for simultaneous determination of serological profile and estimation of duration post HIV infection
#60Compositions and cell-based methods for monitoring the activity of a Dengue Virus protease
#61METHOD FOR DESIGNING A DRUG REGIME FOR HIV-INFECTED PATIENTS
#62Modification of cupredoxin derived peptides
#63Compositions and methods for determining whether a subject would benefit from co-receptor inhibitor therapy
#64MICROFLUIDIC CAPTURE AND DETECTION OF BIOLOGICAL ANALYTES
#65Method for reducing HIV-1 reservoir size using multivalent immunogen and reservoir purging agent
#66COMPOSITIONS AND METHODS FOR CAPTURING EXOSOMES
#67METHODS AND APPARATUS FOR CONDUCTING MULTIPLE MEASUREMENTS ON A SAMPLE
#68Compositions, systems and methods for gene expression noise drug screening and uses thereof
#69Compounds that bind to human immunodeficiency virus rev response element
#70Methods, devices, and systems for sample analysis
#71NOVEL NON-INVASIVE METHODS OF MONITORING HIV VIRAL LOADS
#72Method of efficient extraction of protein from cells
#73Methods for evaluating viral receptor/co-receptor usage and inhibitors of virus entry using recombinant virus assays
#74Cyclic HIV-1 Env V3 glycopeptide immunogens
#75CGRP RECEPTOR AGONIST FOR HIV TREATMENT OR PREVENTION
#76Compositions and methods for identifying enzyme and transport protein inhibitors
#77Compositions for preventing and/or treating an infection by an HIV-1 virus
#78HMGB1 and anti-HMGB1 antibodies for the prognostic of neurological disorders
#79Solid support comprising HIV-1 clade C envelope peptides for the detection of HIV-1-specific antibodies
#80Diagnostic, prognostic, therapeutic and screening protocols
#81METHODS AND KITS FOR THE DETECTION OF VIRAL INFECTIONS
#82DETERMINING DISEASE STATES USING BIOMARKER PROFILES
#83Method for designing a drug regime for HIV-infected patients
#84Detection, capture and quantification of biological moieties from unprocessed bodily fluids using nanoplasmonic platform
#85Compositions and Methods for Reactivating Latent Immunodeficiency Virus
#86Method for quantitating total HMGB1 protein in biological samples
#87Method for blocking HIV entry into dendritic cells by inhibiting sialoadhesin-sialyllactose binding interactions with gangliosides
#88HMGB1 and anti-HMGB1 antibodies for the prognostic of neurological disorders
#89Assembly for determining the presence or absence of an analyte in a blood sample and analysis unit comprising such an assembly
#90Monoclonal antibodies directed against a novel pathogenic west African human immunodeficiency virus type 2 (HIV-2) group F isolate
#91Monitoring and inhibiting human immunodeficiency virus infection by modulating HMGB1 dependent triggering of HIV-1 replication and persistence
#92Monitoring and inhibiting human immunodeficiency virus infection by modulating HMGB1 dependent triggering of HIV-1 replication and persistence
#93Fitness assay and associated methods
#94Compounds and therapeutic applications related to inhibition of dendritic cell immunoreceptor (DCIR) activity and signaling events
#95HMGB1 and anti-HMGB1 antibodies for the prognostic of neurological disorders
#96Biomarkers to identify HIV-specific T-cell subsets
#97COMPARATIVE LIGAND MAPPING FROM MHC CLASS I POSITIVE CELLS
#98COMPARATIVE LIGAND MAPPING FROM MHC POSITIVE CELLS
#99TRIM5alpha mutants and uses thereof
#100Method for the detection of HIV-1-specific antibodies utilizing a Vpu polypeptide
#101Compositions and methods for treating renal disease
#102Compositions and methods for assessing cytotoxicity of single cells
#103Pathogenic west african human immunodeficiency virus type 2 (HIV-2) group F isolate
#104MOUSE MODELS
#105ELECTROCHEMICAL METHOD AND APPARATUS OF IDENTIFYING THE PRESENCE OF A TARGET
#106Compositions and methods for identifying enzyme and transport protein inhibitors
#107Method and a Kit To Detect Malignant Tumors and Provide a Prognosis
#108HIV FUSION INHIBITOR PEPTIDES WITH IMPROVED BIOLOGICAL PROPERTIES
#109IP-10 BASED IMMUNOLOGICAL MONITORING
#110IN VITRO METHOD TO DETERMINE WHETHER A DRUG CANDIDATE ACTIVE AGAINST A TARGET PROTEIN IS ACTIVE AGAINST A VARIANT OF SAID PROTEIN
#111Antibody-secreting cell assay
#112BIOSENSOR FOR DETECTING ANTI-HIV ANTIBODIES
#113Monitoring and inhibiting human immunodeficiency virus infection by modulating HMGB1 dependent triggering of HIV-1 replication and persistence
#114Glycan markers and autoantibody signatures in HIV-1 and HIV-1-associated malignancies
#115Methods, agents and peptides for inducing an innate immune response in HIV vaccination
#116Methods for cyclic nucleotide determination
#117Methods and apparatus for conducting multiple measurements on a sample
#118Compositions for treating HIV infection with cupredoxin and cytochrome C
#119Methods for determining the presence of antibodies blocking viral infection
#120GENETIC DETECTION OF HIV-1 STRAINS THAT USE THE CXCR4 CO-RECEPTOR
#121IMMUNOASSAY APPARATUS AND IMMUNOASSAY METHOD
#122Heteroduplex tracking assay
#123METHODS AND REAGENTS FOR VIRUS ISOLATION AND DETECTION
#124COMPOSITIONS AND METHODS FOR DETECTING AND TREATING HIV INFECTIONS
#125Blood monocyte CD163 expression as a biomarker in HIV-1 infection and neuroaids
#126Methods for Detecting Metabolic States by Laser Ablation Electrospray Ionization Mass Spectrometry
#127COMPOSITIONS AND METHODS TO PREVENT AND/OR TREAT CANCER WITH PA-CARD
#128CONSTRAINED HIV V3 LOOP PEPTIDES AS NOVEL IMMUNOGENS AND RECEPTOR ANTAGONISTS
#129Methods and Compositions for Determining Altered Susceptibility of HIV-1 to Protease Inhibitor Treatment
#130METHOD OF MONITORING HIV INFECTION
#131Irreversibly-inactivated pepsinogen fragment and pharmaceutical compositions comprising the same for detecting, preventing and treating HIV
#132Methods and compositions related to the structure and function of APOBEC3G
#133Compositions and methods for determining whether a subject would benefit from co-receptor inhibitor therapy
#134Monitoring and inhibiting human immunodeficiency virus infection by modulating HMGB1 dependent triggering of HIV-1 replication and persistence
#135Inactivated pepsin fragments for modulating immune system activity against human malignant tumor cells
#136Method for designing a drug regime for HIV-infected patients
#137Compositions and methods to prevent cancer by stabilizing P53 through non MDM2-mediated pathways
#138IP-10 based immunological monitoring
#139Crystal structure of the catalytic domain of the viral restriction factor APOBEC3G
#140PATHOGEN BINDING
#141Detection of HIV-1 infection
#142Modified cupredoxin derived peptides
#143Novel assay for precursor T-cells having high proliferative capacity (PHPC-asay)
#144Semi-quantitative immunochromatographic device and method for the determination of HIV/AIDS immune-status via measurement of soluble CD40 Ligand/CD154, A CD4+ T cell equivalent and the simultaneous detection of HIV infection via HIV antibody detection
#145Method for the identification of human immunodeficiency virus related antibodies in blood
#146Method to measure and characterize microvesicles in the human body fluids
#147Compositions and methods to concurrently treat or prevent multiple diseases with cupredoxins
#148Antigen specific fluorescent nanoparticles
#149Compositions and methods for treating HIV infection with cupredoxin and cytochrome c
#150Method of efficient extraction of protein from cells
#151Analysis of HIV-1 coreceptor use in the clinical care of HIV-1-infected patients
#152Method for identifying agents capable of inhibiting APOBEC3C activity in HIV-infected cells
#153HIV fusion inhibitor peptides with improved biological properties
#154Semi-quantitative immunochromatographic device and method for the determination of HIV/AIDS immune-status via measurement of soluble CD40 ligand/CD 154, A CD4+T cell equivalent
#155Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics
#156Mutational profiles in HIV-1 protease correlated with phenotypic drug resistance
#157Heteroduplex tracking assay
#158ANALYSIS OF HIV-1 CORECEPTOR USE IN THE CLINICAL CARE OF HIV-1 INFECTED PATIENTS
#159Methods for producing fusion polypeptides or enhancing expression of fusion polypeptides
#160HLA Epitope Identification
#161Markers for Memory T Cells and Uses Thereof
#162Immunoglobin IgG3 as a marker for protecting against infectious viral diseases, and the uses of the same
#163Method for simultaneously detecting an antigen of, and an antibody against, an infectious microorganism
#164ANALYSIS OF HIV-1 CORECEPTOR USE IN THE CLINICAL CARE OF HIV-1-INFECTED PATIENTS
#165Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1 (INI1)/hSNF5
#166Constrained Hiv V3 Loop Peptides as Novel Immunogens and Receptor Antagonists
#167Compositions and methods for treating HIV infection with cupredoxin and cytochrome c
#168Epitope escape mutations
#169Compositions For Detection Of Latent Hiv Reactivation And Methods Of Using The Same
#170Method for treatment of HIV infection
#171Analysis of HIV-1 coreceptor use in the clinical care of HIV-1-infected patients
#172Method of treating HIV infection
#173Compositions and methods for detecting and treating HIV infections
#174Anti-HIV antibody
#175Potentiation of the immune response
#176Heteroduplex tracking assay
#177Single-molecule platform for drug discovery: methods and apparatuses for drug discovery, including discovery of anticancer and antiviral agents
#178Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity
#179Integrase-dirived HIV-inhibiting agents
#180Method and compositions for identifying anti-hiv therapeutic compounds
#181HIV fusion inhibitor peptides with improved biological properties
#182Methods for cyclic nucleotide determination
#183IMMUNOASSAY FOR HIV PROTEASE INHIBITORS
#184Comparative ligand mapping from MHC positive cells
#185Methods of treatment and diagnosis using modulators of virus-induced cellular gene sequences
#186Assay
#187Method for reducing HIV viral budding by administering a VPS28-specfic antibody that disrupts Gag-TSG101-VPS28 binding interactions
#188Methods and compositions for treatment of tumors using nucleic acid ligands to platelet-derived growth factor
#189Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds
#190Suppression of HIV-1 replication via inhibition of human flap endonuclease-1-mediated HIV-1 central DNA flap processing
#191Compositions and methods for treating HIV infection with cupredoxin and cytochrome c
#192Method for determining the mechanism of HIV RT inhibitors
#193Retroviral protease inhibitor combinations
#194Heteroduplex tracking assay
#195Processes for identifying quadruplex-targeted antiviral molecules
#196Method for treatment of HIV infection
#197Non nucleoside reverse transcriptase inhibitors
#198Immunoassay for HIV protease inhibitors
#199Method and compositions for identifying anti-hiv therapeutic compounds
#200Tenascin-C nucleic acid ligands
#201Irreversibly-inactivated pepsinogen fragment and pharmaceutical compositions comprising the same for detecting, preventing, and treating HIV
#202High affinity TGFbeta nucleic acid ligands and inhibitors
#203Method of producing and screening antibodies produced in transgenic plants
#204Immunoassay for HIV protease inhibitors
#205Nucleotide sequences derived from the gene of HIV-1
#206Live cell biosensors
#207Compositions and methods for determining resistance to inhibitors of virus entry using recombinant virus assays
#208Screening methods for the identification of agents that inhibit SIRT1 Tat deacetylase activity
#209Assay for TSG101 as inhibitors of HIV production
#210Method and compositions for identifying anti-HIV therapeutic compounds
#211Mutational profiles in HIV-1 protease correlated with phenotypic drug resistance
#212Functional inactivation of cxcr4-mediated responses in growth hormone transgenic mice through socs53 upregulation
#213Novel "Cleave-N-Read" system for protease activity assay and methods of use thereof
#214Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
#215Compositions and methods for evaluating viral receptor/co-receptor usage and inhibitors of virus entry using recombinant virus assays
#216Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds
#217Non nucleoside reverse transcriptase inhibitors
#218Soluble complex comprising a retroviral surface glycoprotein
#219Enhancing anti-HIV efficiency through multivalent inhibitors targeting oligomeric gp120
#220Interrupted, vertical flow testing device
#221Fitness assay and associated methods
#222Biochip kit comprising biochip based on antigen-antibody reactions, and its usage
#223Immunoglobulin IgG3 as a marker for protecting against infectious viral diseases, and the uses of the same
#224Truncation SELEX method
#225Single cell assessment of viral infection/replication
#226Soluble complexes of amylod β peptide and peptidyl prolyl isomerase chaperone and methods of making and using them
#227Cytidine deaminase activators, deoxycytidine deaminase activators, Vif antagonists, and methods of screening for molecules thereof
#228High affinity RNA ligands of basic fibroblast growth factor
#229HIV-1, HIV-2, and SIV nucleotide fragments
#230HIV-specific T-cell induction
#231Lentivirus assay system including Vif protein activity
#232TSG101 as inhibitor of HIV production
#233Potentiation of the immune response
#234Devices and methods to monitor HIV-infection in presence of substance of abuse and/or therapeutic agent